Beurskingpin schreef op 11 september 2018 17:15:
Platform worth €22.50/share. Filgotinib entering phase 3 is arguably proof of the platform. We assume that even if all of
Galapagos' current candidates were to fail, it would still be able to monetise the platform. The proof of course is in the numbers
and based on deals and milestones (collected and future), we can at least say the platform is creating value. We assign a value of
€1B (€22.5/share).